Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Turcot syndrome × DEAE-Dextran × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1 Turcot syndrome 1 Pancreatic Neoplasms 1 Oligoprogressive 1 Lymphatic Metastasis 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Cancer Patients 1

Interventions

pembrolizumab 9 Nivolumab 8 Neoadjuvant Therapy 3 Ipilimumab 3 sintilimab 2 durvalumab 2 avelumab 2 atezolizumab 2 Immune Checkpoint Inhibitors 2 toripalimab 1 tislelizumab 1 spartalizumab 1 relatlimab 1 regorafenib 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 denileukin diftitox 1 danvatirsen 1 Taxes 1 Surgical Procedures, Operative 1 Specimen Handling 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Oxaliplatin 1 Megestrol Acetate 1 Medroxyprogesterone Acetate 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07403877 2026-02-11

TORCH-OPTIMA

Fudan University

Phase 2 Not yet recruiting

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡